XTL Biopharmaceuticals Ltd. said Nasdaq staff has issued a delisting determination, citing the staff’s view that the company is a public shell after its wholly owned subsidiary, The Social Proxy, entered insolvency proceedings and was ordered into liquidation on Feb. 22, 2026. XTL plans to request a hearing to appeal the delisting, and must submit the hearing request by March 4, 2026; otherwise, trading of its ADSs is set to be suspended at the opening of business on March 6, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XTL Biopharmaceuticals Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202602271630PRIMZONEFULLFEED9663171) on February 27, 2026, and is solely responsible for the information contained therein.